The global hyaluronidase market size was valued at USD 901.5 Million in 2022 and is likely to reach USD 1,884.2 Million by 2031, expanding at a CAGR of 8.6% during the forecast period, 2023–2031. The market growth is attributed to the increasing penetration through different applications and the incidence of multiple case studies to demonstrate product efficiency.
Hyaluronidase is an enzyme that breaks down hyaluronic acid, a substance that is found in the body. In medical applications, hyaluronidase is used to help distribute other medications throughout the body or to enhance the absorption of drugs that have been injected into the skin or tissues.
Hyaluronidase is also used in some cosmetic procedures to break down the hyaluronic acid-based fillers that have been injected into the skin. In addition to its cosmetics and medical applications, hyaluronidase has been studied for its potential use in treating conditions such as dry eye syndrome, osteoarthritis, and certain skin disorders.
In the medical field, hyaluronidase is used to speed up the absorption of other injected substances, such as filler injections, by breaking down the hyaluronic acid in the surrounding area. This helps to distribute the injected substance evenly and more rapidly.
Hyaluronidase works by breaking the bonds between the individual molecules of hyaluronic acid, causing it to become more fluid and allowing other substances to be absorbed more easily. The enzyme is usually injected directly into the area being treated and takes effect within a matter of minutes.
It is important to note that hyaluronidase should only be administered by a trained medical professional, as the proper dosage and administration technique is crucial for achieving the desired result and avoiding potential side effects.
Hyaluronidase therapy supports dissolving subcutaneous nodules and correcting excessive injected hyaluronidase fillers. Professionals have increased in the cosmetic industry for gaining knowledge about its adverse effects, use, and applications, due to this cosmetic interest. In the hyaluronic acid fillers management adoption of enzymes has increased, due to these factors.
Though, there are some symptoms of overdose which are sweating, vision, and confusion among others. The beautician or practitioner should be skilled and knowledgeable about the appropriate dosage of hyaluronidase including information about required remedies and possible complications.
In June 2021, SoftFil Cosmetics has created Topilase, a natural alternative to injectable hyaluronidase. Topilase is an innovative care product created by an anesthesia doctor. It is a non-injectable patented skincare product composed of ingredients of natural origin capable of smoothing out irregularities, adjusting the level of hyaluronic acid present in the skin, or even reabsorbing excess product.
The market report finds that the COVID-19 pandemic has negatively impacted the growth of the hyaluronidase market. Treatment for cancer patients has faced difficulties during the pandemic. While the pandemic has complicated the treatment for cancer patients, it is also encouraged creative solutions to challenges in clinical care and research into the new disease is benefiting from insights over years of cancer research.
Hyaluronidase Market Dynamics
The global hyaluronidase market report has up-to-date insights that help in formulating a strategic roadmap about the estimated market scenario and performance during 2023 to 2031.
Major Drivers
The increasing awareness about the change in physical appearance is expected to drive the growth of the market, due to the increasing demand for cosmetics and aesthetic procedures. The increase in the prevalence of skin disorders and easy access to advanced cosmetic treatments is propelling the demand for hyaluronidase in cosmetic dermatology.
Moreover, the growing prevalence of cancer, technological advancements, and various applications in cancer therapy is projected to fuel the market expansion over the forecast period. The Growing number of people opting for aesthetic nonsurgical procedures, a rising geriatric population, and favorable reimbursement policies are anticipated to boost the market growth.
Existing Restraints
Several side effects of the product such as dizziness, rapid heartbeats, unusual weakness, and skin rashes are projected to impede the market growth over the forecast period. Some of the side effects occur and they need medical attention. Some side effect occurs due to overdoses such as swelling, redness, blurred vision, sweating, and others that hamper the growth of the market.
Emerging Opportunity
Rising advanced targets toward reducing the side effects are expected to create lucrative opportunities for the growth of the hyaluronidase market. Rapid technological advancements increasing in research & development (R&D) are likely to offer lucrative opportunities for the market growth.
Scope of Hyaluronidase Market Report
The global hyaluronidase market research report includes an assessment of the market trends, market segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Hyaluronidase Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2016–2021
|
|
Forecast Period
|
2023–2031
|
|
Segmentation
|
Type (Animal-derived, and Synthetic), and Application (Dermatology, Chemotherapy, Ophthalmology, Plastic Surgery, and Others)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Hyaluronidase Market Size and Analysis, Competitive Landscape, Growth Factors, Market Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Takeda Pharmaceutical Company Limited.; Amphastar Pharmaceuticals, Inc.; Halozyme, Inc.; Bausch Health; The Cooper Companies Inc.; Sun Pharmaceutical Industries Ltd.; STEMCELL Technologies.; A CooperSurgical Fertility Company; Calzyme; Creative Enzymes.; and Health Biotech Limited
|
Hyaluronidase Market Segment Insights
Type Segment Analysis
Based on type, the market is segmented into animal-derived and synthetic hyaluronidase. The animal-derived segment is expected to expand at a significant growth rate during the projection period. Various commercial and approved brands are present in the market which are derived from animal sources.
Though, limitations related to animal-derived products have encouraged the development and usage of synthetic products. The safety and quality of local anesthetic blocks have been enhanced by the high efficacy of recombinant human hyaluronidase. To make sure the correct selection of products, professionals must aware of the different properties of sources.
While recommending therapy Practitioners must analyze the products from confirmed sources to make informed decisions. The most widely used animal sources are bovine and porcine products whereas synthetic products include human recombinant sources.
Application Segment Analysis
On the basis of application, the market is divided into dermatology, chemotherapy, ophthalmology, plastic surgery, and others. The chemotherapy segment is expected to grow at a rapid pace during the forecast period. Hyaluronidase Injections are employed in chemotherapy indications.
Many case studies and research recommended its use to resolve hyaluronidase for extravasation. Utility as a complement in chemotherapy is related to improved tumor response to chemotherapeutic drugs. Usage of hyaluronidase is increased majorly in medicine, to augment the dispersion and absorption of other injected drugs.
Regional Analysis
In terms of region, the global hyaluronidase market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to dominate the market during the projection period.
The regional market growth can be attributed to the occurrence of the large number of dermatology clinics prescribing such treatments, the presence of major players who manufactures these products, and the high acceptance of advanced treatment.
Asia Pacific is expected to exhibit a rapid growth rate in the coming years, due to the importance of medical tourism for dermatology treatments and chemotherapy applications in several countries. This has encouraged numerous international companies to interments in the Asia Pacific region. The prevalence of a large number of suppliers along with advanced technology in South Korea is driving the growth of the market in the region.
Segments
The global hyaluronidase market has been segmented on the basis of
Type
Application
- Dermatology
- Chemotherapy
- Ophthalmology
- Plastic Surgery
- Others
Region
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Takeda Pharmaceutical Company Limited.
- Amphastar Pharmaceuticals, Inc.
- Halozyme, Inc.
- Bausch Health
- The Cooper Companies Inc.
- Sun Pharmaceutical Industries Ltd.
- STEMCELL Technologies.
- A CooperSurgical Fertility Company
- Calzyme
- Creative Enzymes.
- Health Biotech Limited
Competitive Landscape
Key players competing in the global hyaluronidase market are Takeda Pharmaceutical Company Limited.; Amphastar Pharmaceuticals, Inc.; Halozyme, Inc.; Bausch Health; The Cooper Companies Inc.; Sun Pharmaceutical Industries Ltd.; STEMCELL Technologies.; A CooperSurgical Fertility Company; Calzyme; Creative Enzymes.; and Health Biotech Limited
These companies adopted development strategies including mergers, acquisitions, partnerships, collaboration, product launches, and production expansion to expand their consumer base worldwide.
- In June 2022, Takeda announced positive results from the double-blind phase 3 clinical trial evaluating HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase]. HYQVIA is for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).
Request For Customization
Enquiry Before Buying
Speak With Analyst
